ADEF
TNGX icon

ABS Direct Equity Fund’s Tango Therapeutics TNGX Stock Holding History

ABS Direct Equity Fund’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
+31
New +$766 0.08% 105

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ABS Direct Equity Fund's TNGX Position: Q2 2026 in Review

ABS Direct Equity Fund opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 31 shares worth $134K. The stake represents 0.08% of the portfolio and ranks #105 among its holdings.

247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • ABS Direct Equity Fund held 31 shares of Tango Therapeutics worth $134K as of Q2 2026.
  • Tango Therapeutics was a new ABS Direct Equity Fund position in Q2 2026.
  • Tango Therapeutics made up 0.08% of ABS Direct Equity Fund's portfolio in Q2 2026, its #105 holding.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.